Johns Hopkins Study Links Liver and Brain to Rare Epilepsy Symptoms
Liver and brain tissues drive distinct and separate symptoms of a rare genetic epilepsy, according to a federally funded study published in Science Advances. Researchers at Johns Hopkins Medicine determined through mouse models that genetic mutations in the ALDH7A1 gene cause seizures through liver cell dysfunction, while psychiatric symptoms stem from specialized brain cells known as astrocytes.
-
Key Clinical Takeaways:
- Loss of the ALDH7A1 gene in liver cells increases susceptibility to seizures in genetically engineered mice.
- Depletion of the same gene specifically in brain astrocytes produces behavioral deficits like depressive-like coping, without altering seizure thresholds.
- The antioxidant compound sulforaphane successfully reversed psychiatric symptoms in the test models without affecting seizure activity.
Cellular Origins of Pyridoxine-Dependent Epilepsy Symptoms
Pyridoxine-dependent epilepsy, or PDE, is caused by loss-of-function mutations in the ALDH7A1 gene. While high doses of vitamin B6 control severe seizures in people with the disorder, psychiatric and cognitive complications frequently persist. To uncover why these dual symptoms manifest, investigators engineered mice in which ALDH7A1 could be selectively deleted from specific tissues. Mice lacking the gene solely in the liver developed heightened seizure susceptibility but maintained normal behavior. Conversely, mice lacking the gene strictly in astrocytes exhibited behavioral deficits while remaining seizure-resistant. These findings demonstrate that neurological and psychiatric signs of the same genetic mutation arise through separate metabolic pathways.
Antioxidant Defenses and the Role of Astrocytes
The absence of ALDH7A1 in astrocytes disrupts normal antioxidant defenses that manage reactive molecules and preserve cellular health. This disruption lowers neuronal activity within the prelimbic cortex, a brain region that regulates emotional responses. Akira Sawa, M.D., director of the Johns Hopkins Schizophrenia Center and professor of psychiatry and behavioral sciences at Johns Hopkins Medicine, explains that understanding these separate mechanisms changes how researchers view complex disorders. “An important implication of this work is that the symptoms we see in a rare neurological disorder do not necessarily have to come from the same place or through the same mechanism,” Sawa states.
Sulforaphane as a Targeted Supplemental Treatment
Because astrocyte dysfunction stems from redox imbalance, the study evaluated sulforaphane, an antioxidant compound found naturally in broccoli sprouts. Sulforaphane activates NRF2, a cellular pathway protecting cells from oxidative stress. Incorporating the compound into the diets of ALDH7A1-deficient mice increased NRF2 levels and restored antioxidant protection in astrocytes. The treatment successfully reversed psychiatric phenotype markers in the test subjects, though it did not prevent seizures. “The fact that sulforaphane could improve the psychiatric phenotype while not preventing seizures was especially informative,” Sawa notes. “It suggests that targeting the biology of the brain directly may be able to address psychiatric symptoms that persist even when the seizures themselves are controlled.” The research was funded by the National Institute of Mental Health and the National Institute on Drug Abuse.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.